HSD17B2

Across TCGA pan-cancer cohorts, HSD17B2 RNA differs between tumor and matched normal tissue in 10 of 18 cancer types tested, making tumor–normal expression one of HSD17B2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where HSD17B2 RNA is repressed in tumor relative to normal tissue. In most cancer types HSD17B2 is over-expressed in tumor, although a few such as COAD and BRCA show the opposite, repressed pattern.

COAD, BRCA, and UCEC are the cancer types where HSD17B2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HSD17B2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	Female	III,IV	−3.656	<.001	11	view →
BRCA	Female	All	−0.924	<.001	6	view →
UCEC	All	All	+0.455	<.001	6	view →
READ	All	All	−3.063	<.001	5	view →
KICH	Female	All	−1.344	<.001	5	view →
LUAD	All	III,IV	−0.311	.005	3	view →
LIHC	Male	All	−1.204	<.001	2	view →
PRAD	All	All	−0.285	.001	2	view →
CHOL	Female	All	−1.856	.031	1	view →
THCA	Male	All	+0.041	.029	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 10 lineages.

HSD17B2–COAD

Open the COAD breakdown →